FLNA
FDA Lifts Clinical Hold on FILANA's Simufilam in TSC Epilepsy
Filana Therapeutics can start a 40-patient Phase 2a study of simufilam in TSC-related epilepsy, with screening expected by the first quarter of 2027.
FLNA
Market-moving news on Filana Therapeutics (NASDAQ: FLNA): filings, earnings, deals and other events, from REDFILED.